Daniel Levitt

3.3k total citations
117 papers, 2.6k citations indexed

About

Daniel Levitt is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Daniel Levitt has authored 117 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Immunology, 39 papers in Oncology and 27 papers in Molecular Biology. Recurrent topics in Daniel Levitt's work include Immune Cell Function and Interaction (19 papers), Monoclonal and Polyclonal Antibodies Research (16 papers) and T-cell and B-cell Immunology (15 papers). Daniel Levitt is often cited by papers focused on Immune Cell Function and Interaction (19 papers), Monoclonal and Polyclonal Antibodies Research (16 papers) and T-cell and B-cell Immunology (15 papers). Daniel Levitt collaborates with scholars based in United States, Cameroon and Australia. Daniel Levitt's co-authors include Albert Dorfman, Matthew A. Cooper, Pei-Lee Ho, Martha K. Dagg, Max D. Cooper, Jonathan Bard, Scott Wieland, Linda M. Hendershot, John A. Thompson and Catherine Lindgren and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Daniel Levitt

111 papers receiving 2.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel Levitt United States	30	989	742	619	359	356	117	2.6k
L K Trejdosiewicz United Kingdom	32	1.2k 1.2×	838 1.1×	405 0.7×	322 0.9×	195 0.5×	78	3.7k
Yong Sung Choi United States	35	1.6k 1.7×	974 1.3×	462 0.7×	169 0.5×	295 0.8×	116	3.4k
J. Alero Thomas United Kingdom	29	1.2k 1.2×	440 0.6×	1.1k 1.8×	211 0.6×	308 0.9×	57	3.0k
Masatoshi Tateno Japan	28	1.5k 1.5×	1.2k 1.6×	720 1.2×	538 1.5×	139 0.4×	72	3.9k
Kashi Javaherian United States	26	1.2k 1.2×	2.0k 2.7×	510 0.8×	140 0.4×	671 1.9×	40	4.4k
Alberto Amadori Italy	34	1.3k 1.3×	1.5k 2.0×	1.3k 2.1×	194 0.5×	182 0.5×	108	4.0k
J. Martin Brown United States	30	824 0.8×	748 1.0×	1.0k 1.6×	378 1.1×	164 0.5×	60	3.3k
Don L. Siegel United States	34	607 0.6×	1.0k 1.4×	742 1.2×	904 2.5×	634 1.8×	107	3.4k
Jean Roudier France	39	1.5k 1.5×	781 1.1×	668 1.1×	392 1.1×	962 2.7×	136	4.1k
Gregory R. Johnson Australia	26	907 0.9×	822 1.1×	449 0.7×	719 2.0×	141 0.4×	55	2.4k

Countries citing papers authored by Daniel Levitt

Since Specialization

Citations

This map shows the geographic impact of Daniel Levitt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Levitt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Levitt more than expected).

Fields of papers citing papers by Daniel Levitt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Levitt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Levitt. The network helps show where Daniel Levitt may publish in the future.

Co-authorship network of co-authors of Daniel Levitt

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Levitt. A scholar is included among the top collaborators of Daniel Levitt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Levitt. Daniel Levitt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Grosso, Ashley, Anna L. Bowring, Iliassou Mfochive Njindam, et al.. (2023). Sexually Transmitted Infection Risks and Symptoms Heightened Among Female Sex Workers who Started Selling Sex Before the Age of 18 in Five Cities in Cameroon. AIDS and Behavior. 28(3). 898–906.

Lyons, Carrie, Anna L. Bowring, Iliassou Mfochive Njindam, et al.. (2022). Modeling the potential impact of pre-exposure prophylaxis for HIV among men who have sex with men in Cameroon. BMC Infectious Diseases. 22(1). 751–751. 4 indexed citations

Lyons, Carrie, Michele R. Decker, Sosthenes Ketende, et al.. (2019). Lifetime experiences of gender-based violence, depression and condom use among female sex workers in Cameroon. International Journal of Social Psychiatry. 65(6). 445–457. 23 indexed citations

Bowring, Anna L., Sosthenes Ketende, Amrita Rao, et al.. (2019). Characterising unmet HIV prevention and treatment needs among young female sex workers and young men who have sex with men in Cameroon: a cross-sectional analysis. The Lancet Child & Adolescent Health. 3(7). 482–491. 26 indexed citations

Eilber, Frederick C., Kamalesh K. Sankhala, Sant P. Chawla, et al.. (2017). Administration of aldoxorubicin and 14 days continuous infusion of ifosfamide/mesna in metastatic or locally advanced sarcomas.. Journal of Clinical Oncology. 35(15_suppl). 11051–11051. 5 indexed citations

Chawla, Sant P., Kamalesh K. Sankhala, Erlinda M. Gordon, et al.. (2016). First line therapy with aldoxorubicin and 14 days continuous infusion of ifosfamide/mesna in metastatic or locally advanced sarcomas: a phase I-II study. Annals of Oncology. 27. vi487–vi487. 1 indexed citations

Marrero, Luis, Dorota Wyczechowska, Anna Wilk, et al.. (2014). Therapeutic Efficacy of Aldoxorubicin in an Intracranial Xenograft Mouse Model of Human Glioblastoma. Neoplasia. 16(10). 874–882. 31 indexed citations

Sands, Bruce E., William J. Sandborn, Tom Creed, et al.. (2012). Basiliximab Does Not Increase Efficacy of Corticosteroids in Patients With Steroid-Refractory Ulcerative Colitis. Gastroenterology. 143(2). 356–364.e1. 26 indexed citations

Levitt, Daniel, et al.. (2001). Phase II Trial of Remitogen™ (Humanized 1D10) Monoclonal Antibody Targeting Class II in Patients with Relapsed Low-Grade or Follicular Lymphoma. Clinical Lymphoma. 2(3). 188–190. 24 indexed citations

10.

Rinehart, J. J., Kim Margolin, Pierre L. Triozzi, et al.. (1995). Phase I trial of recombinant interleukin 3 before and after carboplatin/etoposide chemotherapy in patients with solid tumors: a southwest oncology group study.. PubMed. 1(10). 1139–44. 3 indexed citations

11.

Tepler, I, Anthony Elias, Leslie A. Kalish, et al.. (1994). Effect of recombinant human interleukin‐3 on haematological recovery from chemotherapy‐induced myelosuppression. British Journal of Haematology. 87(4). 678–686. 14 indexed citations

12.

Thomassen, Mary Jane, Joyce Antal, Mary J. Connors, et al.. (1993). Immunomodulatory Effects of Recombinant Interleukin-3 Treatment on Human Alveolar Macrophages and Monocytes. Journal of Immunotherapy. 14(1). 43–56. 5 indexed citations

13.

Smith, Malcolm A., Paul M. Sondel, Andrea Gillespie, et al.. (1992). A Phase I Study of Interleukin-2 in Children with Cancer. Journal of Pediatric Hematology/Oncology. 14(4). 305–311. 23 indexed citations

14.

Sosman, Jeff, Kathleen Schell, Peter Köhler, et al.. (1991). Prolonged Interleukin-2 (IL-2) Treatment Can Augment Immune Activation Without Enhancing Antitumor Activity in Renal Cell Carcinom. Cancer Investigation. 9(1). 35–48. 12 indexed citations

15.

Fallon, Barbara G., et al.. (1991). A phase I study of an outpatient regimen of recombinant human interleukin-2 and alpha-2a-interferon in patients with solid tumors. Cancer. 68(8). 1708–1713. 10 indexed citations

16.

Talpaz, Moshe, Jeanne M. Rothberg, James L. Murray, et al.. (1989). Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2A in cancer patients: a phase I study.. Journal of Clinical Oncology. 7(11). 1726–1732. 73 indexed citations

17.

Hoffman, Mitchel S., Abraham Mittelman, Brad Dworkin, et al.. (1989). Severe intrahepatic cholestasis in patients treated with recombinant interleukin-2 and lymphokine-activated killer cells. Journal of Cancer Research and Clinical Oncology. 115(2). 175–178. 12 indexed citations

18.

Levitt, Daniel, et al.. (1987). B-cell stimulation by T-cell-secreted proteoglycan. Cellular Immunology. 110(2). 425–430. 9 indexed citations

19.

Bard, Jonathan, Jennifer Hall, & Daniel Levitt. (1987). Chlamydia Trachomatis (L2 Serovar) Can Be Bound, Ingested and Destroyed by Differentiated but Not by Undifferentiated Human Promyelocyte Cell Line HL-60. Microbiology. 133(4). 899–910. 4 indexed citations

20.

Levitt, Daniel. (1985). Diagnosis and Evaluation of Tumors by Flow Cytometery. Guthrie Journal. 54(3). 109–118.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact